bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure 1 from Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors
Authors: Hathaway Cassandra A. , Townsend Mary K. , Wang Tianyi , Vinci Christine , Jake-Schoffman Danielle E. , Hecht Jonathan L. , Saeed-Vafa Daryoush , Moran Segura Carlos , Nguyen Jonathan V. , Conejo-Garcia Jose R. , Fridley Brooke L. , Tworoger Shelley S.
Published: June 2024

Supplemental Figure 1: Flow chart for the selection of ovarian cancer cases in the Nurses’ Health Study (NHS) and NHSII, limited to ovarian cancer diagnosis, available tissue, available data on parental smoke exposure, and successful multiplex immunofluorescence staining.
Supplementary Table S9 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Table S9: Model performance using Mavaddat 313-SNP PRS instead of Genomics plc PRS in test data (N=25,369).
Supplementary Table S7 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Table S7: Reclassification tables for Gail model using fixed 5% 10-year risk threshold in test data (N=25,369).
Supplementary Table S6 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Table S6: Reclassification tables for Tyrer-Cuzick model using fixed 5% 10-year risk threshold in test data (N=25,369).
Supplementary Table S5 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Table S5: Hazard ratios (HR) associated with variables in the Gail model
Supplementary Table S4 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Table S4: Hazard ratios (HR) associated with variables in the Tyrer-Cuzick model
Supplementary Table S3 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Table S3: Descriptive statistics of analysis population by quintiles of breast cancer PRSBC
Supplementary Table S1 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Table S1: Derivation of variables for the Tyrer-Cuzick model using UK Biobank data.
Supplementary Figure S4 from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

Supplementary Figure S4: Schoenfeld residual plots from Cox model containing Gail model 10-year risk and PRSBC in training data (N=101,121).
Data from Fine Particulate Matter, Noise Pollution, and Greenspace and Prostate Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort
Authors: Thomas Aleah L. , Rhee Jongeun , Fisher Jared A. , Horner Marie-Josephe , Jones Rena R.
Published: June 2024

AbstractBackground:
Greenspace is hypothesized as being protective against cancer, whereas noise pollution and fine particulate matter (<2.5 μm in diameter, PM2.5) are both potential risk factors. Findings from recent studies of greenspace and PM2.5 with prostate cancer are not conclusive and the association between noise exposure and cancer has not been evaluated in a U.S. study.
Methods:
We assessed PM2.5, noise, and greenspace exposure using spatiotemporal models and satellite-based estimates at enrollment addresses for N = 43,184 male participants of the prospective Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial cohort (enrolled 1994–2001). We used Cox regression models adjusted for age, race and ethnicity, study center, family history of prostate cancer, and Area Deprivation Index to estimate associations between ambient PM2.5 (μg/m3), greenspace (index range from –1 to 1), and noise pollution (loudest 10% of total existing sound, decibels) and incident prostate cancer risk through December 2017.
Results:
A total of 6,327 cases of prostate cancer were diagnosed among male participants during follow-up. PM2.5 and noise exposures were moderately positively correlated (Spearman ρ = 0.46), and PM2.5 and greenspace were not correlated (ρ = 0.10); greenspace and noise were inversely correlated (ρ = −0.32). In single-pollutant and multipollutant models mutually adjusted for coexposures, we found no associations with prostate cancer risk.
Conclusions:
We did not find evidence that PM2.5, greenspace, and noise pollution were associated with prostate cancer risk in this large, geographically spread cohort.
Impact:
This study contributes to a small body of existing literature investigating these biologically plausible associations.
Data from Projecting the Impact of Multi-Cancer Early Detection on Late-Stage Incidence Using Multi-State Disease Modeling
Authors: Lange Jane M. , Gogebakan Kemal Caglar , Gulati Roman , Etzioni Ruth
Published: June 2024

AbstractBackground:
Downstaging—reduction in late-stage incidence—has been proposed as an endpoint in randomized trials of multi-cancer early detection (MCED) tests. How downstaging depends on test performance and follow-up has been studied for some cancers but is understudied for cancers without existing screening and for MCED tests that include these cancer types.
Methods:
We develop a model for cancer natural history that can be fit to registry incidence patterns under minimal inputs and can be estimated for solid cancers without existing screening. Fitted models are combined to project downstaging in MCED trials given sensitivity for early- and late-stage cancers. We fit models for 12 cancers using incidence data from the Surveillance, Epidemiology, and End Results program and project downstaging in a simulated trial under variable preclinical latencies and test sensitivities.
Results:
A proof-of-principle lung cancer model approximated downstaging in the National Lung Screening Trial. Given published stage-specific sensitivities for 12 cancers, we projected downstaging ranging from 21% to 43% across plausible preclinical latencies in a hypothetical 3-screen MCED trial. Late-stage incidence reductions manifest soon after screening begins. Downstaging increases with longer early-stage latency or higher early-stage test sensitivity.
Conclusions:
Even short-term MCED trials could produce substantial downstaging given adequate early-stage test sensitivity.
Impact:
Modeling the natural histories of cancers without existing screening facilitates analysis of novel MCED products and trial designs. The framework informs expectations of MCED impact on disease stage at diagnosis and could serve as a building block for designing trials with late-stage incidence as the primary endpoint.
Data from Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank
Authors: Collister Jennifer A. , Liu Xiaonan , Littlejohns Thomas J. , Cuzick Jack , Clifton Lei , Hunter David J.
Published: June 2024

AbstractBackground:
Previous studies have demonstrated that incorporating a polygenic risk score (PRS) to existing risk prediction models for breast cancer improves model fit, but to determine its clinical utility the impact on risk categorization needs to be established. We add a PRS to two well-established models and quantify the difference in classification using the net reclassification improvement (NRI).
Methods:
We analyzed data from 126,490 post-menopausal women of “White British” ancestry, aged 40 to 69 years at baseline from the UK Biobank prospective cohort. The breast cancer outcome was derived from linked registry data and hospital records. We combined a PRS for breast cancer with 10-year risk scores from the Tyrer–Cuzick and Gail models, and compared these to the risk scores from the models using phenotypic variables alone. We report metrics of discrimination and classification, and consider the importance of the risk threshold selected.
Results:
The Harrell's C statistic of the 10-year risk from the Tyrer–Cuzick and Gail models was 0.57 and 0.54, respectively, increasing to 0.67 when the PRS was included. Inclusion of the PRS gave a positive NRI for cases in both models [0.080 (95% confidence interval (CI), 0.053–0.104) and 0.051 (95% CI, 0.030–0.073), respectively], with negligible impact on controls.
Conclusions:
The addition of a PRS for breast cancer to the well-established Tyrer–Cuzick and Gail models provides a substantial improvement in the prediction accuracy and risk stratification.
Impact:
These findings could have important implications for the ongoing discussion about the value of PRS in risk prediction models and screening.
Supplementary Table S7 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Table S7: Representativeness of Study Participants
Supplementary Table S2 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Authors: Magbanua Mark Jesus M. , Ahmed Ziad , Sayaman Rosalyn W. , Brown Swigart Lamorna , Hirst Gillian L. , Yau Christina , Wolf Denise M. , Li Wen , Delson Amy L. , Perlmutter Jane , Pohlmann Paula , Symmans W. Fraser , Yee Douglas , Hylton Nola M. , Esserman Laura J. , DeMichele Angela M. , Rugo Hope S. , van 't Veer Laura J.
Published: June 2024

Clinicopathologic characteristics and cfDNA concentration in HER2-negative patients receiving neoadjuvant treatment in the I-SPY2 trial.
Supplementary Table S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Table S5: Tissue Distribution of ARO-HIF2 Trigger by miRNAscope™ (H-Score) at Week 2
Supplementary Figure S6 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Authors: Magbanua Mark Jesus M. , Ahmed Ziad , Sayaman Rosalyn W. , Brown Swigart Lamorna , Hirst Gillian L. , Yau Christina , Wolf Denise M. , Li Wen , Delson Amy L. , Perlmutter Jane , Pohlmann Paula , Symmans W. Fraser , Yee Douglas , Hylton Nola M. , Esserman Laura J. , DeMichele Angela M. , Rugo Hope S. , van 't Veer Laura J.
Published: June 2024

Survival curves of patients stratified into two groups, cfDNA high shedders vs. cfDNA low shedders. CfDNA concentration was measured in the plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancer (TNBC). The median cfDNA concentration was used as the cutoff to stratify patients into high vs. low cfDNA-shedders. The survival endpoint was distant recurrence-free survival (DRFS). P values were calculated using the Wald test. Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy before surgery (T3).
Supplementary Figure S5 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Authors: Magbanua Mark Jesus M. , Ahmed Ziad , Sayaman Rosalyn W. , Brown Swigart Lamorna , Hirst Gillian L. , Yau Christina , Wolf Denise M. , Li Wen , Delson Amy L. , Perlmutter Jane , Pohlmann Paula , Symmans W. Fraser , Yee Douglas , Hylton Nola M. , Esserman Laura J. , DeMichele Angela M. , Rugo Hope S. , van 't Veer Laura J.
Published: June 2024

Association between cfDNA concentration and residual cancer burden (RCB). CfDNA concentration was measured in the plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancer (TNBC). Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy (NAC) before surgery (T3). RCB was divided into 4 classes: RCB-0, equivalent to pathologic complete response, and RCB-I, -II, -III, representing limited, moderate, and extensive residual cancer after NAC, respectively. Pairwise P values were calculated using the Wilcoxon rank sum test, with Bonferroni correction to adjust for multiple comparisons.
Supplementary Table S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Table S2: Summary of ARO-HIF2 Plasma Pharmacokinetic Parameters
Supplementary Methods S1 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Supplementary Methods and References
Supplementary Figure S6 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Figure S6: Summary of Hemoglobin (g/dL) by Visit
Supplementary Figure S5 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Figure S5. Summary of Percent Change in Erythropoietin (IU/L) by Visit
Supplementary Table S2 from Upfront Neck Dissection for Treatment Selection and Improvement in Quality of Life as a Novel Treatment Paradigm for Deintensification in HPV+ OPSCC
Authors: Swiecicki Paul L. , Bellile Emily , Dragovic Aleksandar F. , McHugh Jonathan , Udager Aaron , Mierzwa Michelle Lynn , Shah Jennifer , Heft-Neal Molly , Rosko Andrew , Malloy Kelly M. , Casper Keith , Chinn Steven Bennett , Shuman Andrew G. , Stucken Chaz , Chepeha Douglas B. , Wolf Gregory T. , Bradford Carol Rossier , Eisbruch Avraham , Prince Mark E. , Worden Francis P. , Spector Matthew E.
Published: June 2024

Supplementary Table 2: Change in Stage with Neck Dissection
Supplementary Figure S2 from A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Authors: Brugarolas James , Obara Gregory , Beckermann Kathryn E. , Rini Brian , Lam Elaine T. , Hamilton James , Schluep Thomas , Yi Min , Wong So , Mao Zhongping Lily , Gamelin Erick , Tannir Nizar M.
Published: June 2024

Figure S2. Subject Disposition
Supplementary Data 1 from KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes
Authors: Assatova Bimarzhan , Willim Robert , Trevisani Christopher , Haskett Garrett , Kariya Khyati Maulik , Chopra Kusha , Park Sung Rye , Tolstorukov Michael Yevgeniy , McCabe Sean M. , Duffy Jessica , Louissaint Abner , Huuhtanen Jani , Bhattacharya Dipabarna , Mustjoki Satu , Koh Min Jung , Powers Foster , Morgan Elizabeth A. , Yang Lei , Pinckney Brandy , Cotton Matthew J. , Crabbe Andrew , Ziemba Jessica Beth , Brain Ian , Heavican-Foral Tayla B. , Iqbal Javeed , Nemec Ronald , Rider Anna Baird , Ford Josie Germain , Koh Min Ji , Scanlan Nora , Feith David J. , Loughran Thomas P. , Kim Won Seog , Choi Jaehyuk , Roels Juliette , Boehme Lena , Putteman Tom , Taghon Tom , Barnes Jeffrey A. , Johnson P. Connor , Jacobsen Eric D. , Greenberg Steven A. , Weinstock David M. , Jain Salvia
Published: June 2024

Supplementary Methods and Figures
Supplemental Figure 9 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 9. Real-Time killing assay of CAR.GD2 T-cells vs DAOY-GFP cell line pre-treated with Tazemetostat.
Supplemental Figure 4 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 4. Real-Time killing assay of CAR.GD2 T-cells vs D283 Med-GFP-FF-Luc cell line.
Supplemental Figure 16 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 16. Evaluation of the efficacy of AP1903 CAR.GD2 T-cells infiltrating tumor in in vivo MB xenograft mouse model.
Supplemental Figure 14 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 14. Orthotopic PDX mouse model of human MED-411 FH mCherry/Luc cell line to evaluate anti-tumor activity of CAR.GD2 T-cells.
Supplementary Table S2 from A Prospective Double-Blinded Comparison of Reflectance Confocal Microscopy with Conventional Histopathology for In Vivo Assessment in Oral Cancer
Authors: Zanoni Daniella K. , Demétrio De Souza França Paula , Valero Cristina , Peterson Gary , Ardigo Marco , Ghossein Ronald , Dusza Stephen W. , Matsuura Danielli , Scholfield Daniel W. , Adilbay Dauren , Montero Pablo H. , Migliacci Jocelyn , Pillarsetty Naga Vara Kishore , Kose Kivanc , Ganly Ian , Rajadhyaksha Milind , Patel Snehal G.
Published: June 2024

Supplementary Table S2 shows the characteristics found on RCM imaging and on the H&E slides from the patients that the RCM reading did not agree with the histology findings.
Supplemental Figure 12 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 12. DAOY-GFP tumor bearing-mice treated with Tazemetostat to evaluate GD2 upregulation in vivo.
Supplemental Figure 10 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 10. In vivo experiment of NSG mice bearing D283 Med-GFP-FF-Luc cells treated with NT or CAR.GD2 T-cells.
Supplemental Figure 1 from GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Authors: Ciccone Roselia , Quintarelli Concetta , Camera Antonio , Pezzella Michele , Caruso Simona , Manni Simona , Ottaviani Alessio , Guercio Marika , Del Bufalo Francesca , Quadraccia Maria Cecilia , Orlando Domenico , Di Cecca Stefano , Sinibaldi Matilde , Aurigemma Mariasole , Iaffaldano Laura , Sarcinelli Andrea , D'Amore Maria Luisa , Ceccarelli Manuela , Nazio Francesca , Marabitti Veronica , Giorda Ezio , Pezzullo Marco , De Stefanis Cristiano , Carai Andrea , Rossi Sabrina , Alaggio Rita , Del Baldo Giada , Becilli Marco , Mastronuzzi Angela , De Angelis Biagio , Locatelli Franco
Published: June 2024

Supplemental Figure 1. Representative dot plots of GD2 expression in MB patients.
Supplementary Figure S4 from The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer
Authors: Han Yoo Jane , Liu Siyao , Hardeman Ashley , Rajagopal Padma Sheila , Mueller Jeffrey , Khramtsova Galina , Sanni Ayodele , Ajani Mustapha , Clayton Wendy , Hurley Ian W. , Yoshimatsu Toshio F. , Zheng Yonglan , Parker Joel , Perou Charles M. , Olopade Olufunmilayo I.
Published: June 2024

Supplementary Fig. S4. No Correlation with Immune Cell Infiltration in the Basal-like Subtype Tumors.
Supplementary Figure S8 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Authors: Moyer Cassandra L. , Lanier Amanda , Qian Jing , Coleman Darian , Hill Jamal , Vuligonda Vidyasagar , Sanders Martin E. , Mazumdar Abhijit , Brown Powel H.
Published: June 2024

Supplementary figure with additional drug synergy models using ADC
Supplementary Table 1 from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
Authors: D'Alise Anna Morena , Leoni Guido , Cotugno Gabriella , Siani Loredana , Vitale Rosa , Ruzza Valentino , Garzia Irene , Antonucci Laura , Micarelli Elisa , Venafra Veronica , Gogov Sven , Capone Alessia , Runswick Sarah , Martin‐Liberal Juan , Calvo Emiliano , Moreno Victor , Symeonides Stefan N. , Scarselli Elisa , Bechter Oliver
Published: June 2024

Supplementary Table 1. Representativeness of study participants
Supplementary Figure S7 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Authors: Moyer Cassandra L. , Lanier Amanda , Qian Jing , Coleman Darian , Hill Jamal , Vuligonda Vidyasagar , Sanders Martin E. , Mazumdar Abhijit , Brown Powel H.
Published: June 2024

Supplementary figure with additional drug synergy models using TKI
Supplementary Table 9 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

Clinical Table of patients whose longitudinally matched plasma samples were subject to CXCL8 chemokine profiling
Supplementary Figure S2 from IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy
Authors: Moyer Cassandra L. , Lanier Amanda , Qian Jing , Coleman Darian , Hill Jamal , Vuligonda Vidyasagar , Sanders Martin E. , Mazumdar Abhijit , Brown Powel H.
Published: June 2024

Supplementary figure with cell line drug sensitivity
Supplementary Methods S1 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Desai Kunal B. , Serritella Anthony V. , Stadler Walter M. , O'Donnell Peter H. , Sweis Randy F. , Szmulewitz Russell Z.
Published: June 2024

Supplementary SEction (all figures included)
Supplementary Figure S3 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Desai Kunal B. , Serritella Anthony V. , Stadler Walter M. , O'Donnell Peter H. , Sweis Randy F. , Szmulewitz Russell Z.
Published: June 2024

Figure S3: Mean baseline cortisol calculated in twenty (20)
patients at day 1 and day 28
Supplementary Figure S2 from A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Desai Kunal B. , Serritella Anthony V. , Stadler Walter M. , O'Donnell Peter H. , Sweis Randy F. , Szmulewitz Russell Z.
Published: June 2024

Figure S2: Dose levels for dose escalation
Supplementary Table 1 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

Clinical table of PDAC patients in tumor single cell sequencing object
Supplementary Fig 8 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

PDAC Organoids chemoattract myeloid cells in a CXCL8-dependent manner.
Supplementary Fig 7 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

Organoids recapitulate the heterogeneity of human disease and retain unique tumor cell populations characterized by expression of KRT17, CXCL8 and CXCL1.
Supplementary Fig 3 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

KRT17 and CLDN18 are co-expressed in a unique subpopulation of tumor epithelial cells.
Supplementary Fig 11 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

CXCL8 levels in patient plasma correlate with abundance of KRT17high; CXCL8+ cancer cells in treatment naïve patients.
Supplementary Fig 10 from KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment
Authors: Carpenter Eileen S. , Kadiyala Padma , Elhossiny Ahmed M. , Kemp Samantha B. , Li Jay , Steele Nina G. , Nicolle Rémy , Nwosu Zeribe C. , Freeman Julia , Dai Henry , Paglia Daniel , Du Wenting , Donahue Katelyn , Morales Jacqueline , Medina-Cabrera Paola I. , Bonilla Monica E. , Harris Lindsey , The Stephanie , Gunchick Valerie , Peterson Nicole , Brown Kristee , Mattea Michael , Espinoza Carlos E. , McGue Jake , Kabala Sarah M. , Baliira Rachel K. , Renollet Nur M. , Mooney Ayden G. , Liu Jianhua , Bhalla Sean , Farida Jeremy P. , Ko Christopher , Machicado Jorge D. , Kwon Richard S. , Wamsteker Erik-Jan , Schulman Allison , Anderson Michelle A. , Law Ryan , Prabhu Anoop , Coulombe Pierre A. , Rao Arvind , Frankel Timothy L. , Bednar Filip , Shi Jiaqi , Sahai Vaibhav , Pasca Di Magliano Marina
Published: June 2024

CXCL8 levels in patient plasma correlate with abundance of KRT17+ epithelial cells and with prevalence of myeloid cells in matched patient tumors.
Supplementary Table S6 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Authors: Agarwal Neeraj , Castellano Daniel , Alonso-Gordoa Teresa , Arranz Arija Jose Angel , Colomba Emeline , Gravis Gwenaelle , Mourey Loic , Oudard Stephane , Fléchon Aude , González Macarena , Rey Pablo M. , Schweizer Michael T. , Gallardo Enrique , Johnston Erica , Balar Arjun , Haddad Nadine , Appiah Adams K. , Nacerddine Karim , Piulats José M.
Published: June 2024

Pharmacokinetic Summary.
Supplementary Table S5 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Authors: Agarwal Neeraj , Castellano Daniel , Alonso-Gordoa Teresa , Arranz Arija Jose Angel , Colomba Emeline , Gravis Gwenaelle , Mourey Loic , Oudard Stephane , Fléchon Aude , González Macarena , Rey Pablo M. , Schweizer Michael T. , Gallardo Enrique , Johnston Erica , Balar Arjun , Haddad Nadine , Appiah Adams K. , Nacerddine Karim , Piulats José M.
Published: June 2024

Post-discontinuation therapies.
Supplementary Figure S3 from Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers
Authors: Jamieson Amy , Sobral de Barros Juliana , Cochrane Dawn R. , Douglas J. Maxwell , Shankar Sameer , Lynch Branden J. , Leung Samuel , Martin Spencer , Senz Janine , Lum Amy , Drew Yvette , Gilks C. Blake , Huntsman David G. , McAlpine Jessica N.
Published: June 2024

Supplemental figure 3. Representative images of the FISH analysis performed on the validation cohort to verify the absolute copy number generated by the rascal tool. In blue are the nuclei stained with DAPI; Green arrows are pointing to the centromeric probe CEP 7 (SpectrumGreen - Abbott Molecular); Red arrows are pointing to the CEP 11 (SpectrumOrange - Abbott Molecular) probe.
Supplementary Figure S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Authors: Agarwal Neeraj , Castellano Daniel , Alonso-Gordoa Teresa , Arranz Arija Jose Angel , Colomba Emeline , Gravis Gwenaelle , Mourey Loic , Oudard Stephane , Fléchon Aude , González Macarena , Rey Pablo M. , Schweizer Michael T. , Gallardo Enrique , Johnston Erica , Balar Arjun , Haddad Nadine , Appiah Adams K. , Nacerddine Karim , Piulats José M.
Published: June 2024

Summary of patient disposition and list of study inclusion and exclusion criteria. 
Supplementary Table S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Authors: Schatz Christoph A. , Zitzmann-Kolbe Sabine , Moen Ingrid , Klotz Monika , Nair Shankari , Stargard Stefan , Bjerke Roger M. , Wickstrøm Biseth Katrine , Feng Yuan Zeng , Indrevoll Bård , Cruciani Veronique , Karlsson Jenny , Haendler Bernard , Nielsen Carsten H. , Alfsen Maria Z. , Hammer Stefanie , Hennekes Hartwig , Cuthbertson Alan , Hagemann Urs B. , Larsen Åsmund
Published: June 2024

Table S1. Cytotoxicity of 225Ac-pelgi (2 kBq/μg) in PSMA-positive and PSMA-negative prostate cancer cell lines in vitro.
Supplementary Table 4 from Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Authors: Chen Junru , Hu Xu , Zhao Junjie , Yin Xiaoxue , Zheng Linmao , Guo Jingjing , Chen Jianhui , Wang Yongquan , Sheng Xinan , Dong Haiying , Liu Xiaodong , Zhang Xingming , Liang Jiayu , Liu Haolin , Yao Jin , Liu Jiyan , Shen Yali , Chen Zhibin , He Zhengyu , Wang Yaodong , Chen Ni , Nie Ling , Zhang Mengni , Pan Xiuyi , Chen Yuntian , Liu Haoyang , Zhang Yaowen , Tang Yanfeng , Zhu Sha , Zhao Jinge , Dai Jindong , Wang Zilin , Zeng Yuhao , Wang Zhipeng , Huang Haojie , Liu Zhenhua , Shen Pengfei , Zeng Hao , Sun Guangxi
Published: June 2024

Supplementary Table 4. Adverse events that occurred during treatment in 10% or more patients receiving first-line ICI+TKI.
Supplementary Methods S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Authors: Schatz Christoph A. , Zitzmann-Kolbe Sabine , Moen Ingrid , Klotz Monika , Nair Shankari , Stargard Stefan , Bjerke Roger M. , Wickstrøm Biseth Katrine , Feng Yuan Zeng , Indrevoll Bård , Cruciani Veronique , Karlsson Jenny , Haendler Bernard , Nielsen Carsten H. , Alfsen Maria Z. , Hammer Stefanie , Hennekes Hartwig , Cuthbertson Alan , Hagemann Urs B. , Larsen Åsmund
Published: June 2024

Supplementary Methods
Supplementary Figure S7 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Figure S7. Distribution of allograft complications in All of Us.
Supplementary Figure S2 from Stabilizing Tumor-Resident Mast Cells Restores T-Cell Infiltration and Sensitizes Sarcomas to PD-L1 Inhibition
Authors: Panagi Myrofora , Mpekris Fotios , Voutouri Chrysovalantis , Hadjigeorgiou Andreas G. , Symeonidou Chloe , Porfyriou Eleni , Michael Christina , Stylianou Andreas , Martin John D. , Cabral Horacio , Constantinidou Anastasia , Stylianopoulos Triantafyllos
Published: June 2024

In vitro assessment of MC/9 cells.
Supplementary Figure S10 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Figure S10. No evidence for greater transplant complications across the electronic health record lifetime for allograft recipients with clonal hematopoiesis of indeterminate potential.
Supplementary Figure S1 from Solid Organ Transplant Recipients Exhibit More TET2-Mutant Clonal Hematopoiesis of Indeterminate Potential Not Driven by Increased Transplantation Risk
Authors: Silver Alexander J. , Vlasschaert Caitlyn , Mack Taralynn , Sharber Brian , Xu Yaomin , Bick Alexander G. , Pinson C. Wright , Savona Michael R.
Published: June 2024

Supplementary Figure S1. Annual rates of solid organ transplantation in the United States and United Kingdom, 2007-2021.
Supplementary Table S6 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 6. Treatment-related adverse events.
Supplementary Table S4 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 4. List of antibodies used for mass cytometry
Supplementary Table S2 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 2. Representativeness of Study Participants
Supplementary Table S1 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Table 1. Inclusion and exclusion criteria.
Supplementary Table S3 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Authors: Liu Jiangang , Moura David S. , Jones Robin L. , Aggarwal Amit , Ebert Philip J. , Wagner Andrew J. , Wright Jennifer , Martin-Broto Javier , Tap William D.
Published: June 2024

A). The association of molecular subtypes (CC1, CC2, and CC3) with histologic subtype, metastatic site (lung/liver), and tumor grade. B).Tumor responses in different molecular subtypes (CC1, CC2, and CC3). C).Tumor responses by treatment arm (olaratumab + doxorubicin; placebo + doxorubicin).
Supplementary Methods S9 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Methods 9. Gut Microbiome analysis.
Supplementary Methods S8 from Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study
Authors: Pinato David J. , D'Alessio Antonio , Fulgenzi Claudia Angela Maria , Schlaak Alexandra Emilia , Celsa Ciro , Killmer Saskia , Blanco Jesus Miguens , Ward Caroline , Stikas Charalampos-Vlasios , Openshaw Mark R. , Acuti Nicole , Nteliopoulos Georgios , Balcells Cristina , Keun Hector C. , Goldin Robert D. , Ross Paul J. , Cortellini Alessio , Thomas Robert , Young Anna-Mary , Danckert Nathan , Tait Paul , Marchesi Julian R. , Bengsch Bertram , Sharma Rohini
Published: June 2024

Supplementary Methods 8. Immune subtype and related number of genes profiled using the NanoString PanCancer Immune panel.
Supplementary Table S1 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Authors: Liu Jiangang , Moura David S. , Jones Robin L. , Aggarwal Amit , Ebert Philip J. , Wagner Andrew J. , Wright Jennifer , Martin-Broto Javier , Tap William D.
Published: June 2024

ANNOUNCE REDSARC centroids
Supplementary Figure S3 from Best Overall Response–Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
Authors: Liu Jiangang , Moura David S. , Jones Robin L. , Aggarwal Amit , Ebert Philip J. , Wagner Andrew J. , Wright Jennifer , Martin-Broto Javier , Tap William D.
Published: June 2024

Gene expression correlation between HTG EdgeSeq and RNA seq platforms (A) with all common genes and (B) filtering out 37 genes with more than a ten fold difference in expression (ratios above 10 or below 0.1).